<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852486</url>
  </required_header>
  <id_info>
    <org_study_id>EDI-PIO-UNICAMP</org_study_id>
    <nct_id>NCT02852486</nct_id>
  </id_info>
  <brief_title>Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response</brief_title>
  <acronym>EDI-PIO</acronym>
  <official_title>Pilot Study of Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia With Deep Molecular Response - Evaluation of Pioglitazone in Treatment-free Remission (EDI-PIO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate treatment-free remission after imatinib
      discontinuation in patients with chronic myeloid leukemia with deep molecular response.
      Before discontinuation, patients will receive pioglitazone associated with imatinib during 3
      months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of chronic myeloid leucemia (CML) with tyrosine kinase inhibitors (TKIs) changed
      dramatically the prognosis of CML, with high rates of cytogenetic and molecular remission and
      increase of overall and progression-free survival. However, the long-term treatment of CML
      has a high cost to the health system, due to the price of these drugs and the need for
      continued use. In addition, chronic adverse effects may compromise the quality of life of
      patients. Discontinuation trials of TKIs have been developed in order to identify groups of
      patients who may benefit from treatment discontinuation if they have obtained deeper
      molecular responses.The primary objective of this study is to evaluate treatment free
      remission (TFR) after imatinib discontinuation in patients treated for more than 3 years with
      imatinib and with deep molecular response stable for two years (defined in the present study
      as a molecular response of 4.5 log reduction in breakpoint cluster region (BCR)-Abelson
      murine leukemia viral oncogene homolog 1(ABL) transcripts levels according to the
      international scale (MR 4.5; BCR-ABL/ABL ratio &lt; or = 0.0032%). Patients with these criteria
      will receive pioglitazone for 3 months concomitant with imatinib, prior to discontinuation.
      After imatinib discontinuation, patients will be evaluated by molecular assessment of BCR-ABL
      transcripts levels by quantitative real time polymerase chain reaction (RQ-PCR) monthly
      during the first year, every 2 months in the second year and then every 3 months. The
      criteria for restarting treatment will be the loss of major molecular response (MMR),
      documented by a single RQ-PCR test &gt; 0.1%, or confirmed loss of 4 log reduction molecular
      response (MR4.0), by 2 consecutive RQ-PCR tests &gt; 0.01%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-free remission after imatinib discontinuation</measure>
    <time_frame>Through study completion (five years)</time_frame>
    <description>Treatment-free remission time after imatinib discontinuation in patients with CML treated with pioglitazone for 3 months before imatinib discontinuation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 months</time_frame>
    <description>assessment of number of participants with treatment-related adverse events as assessed by CTCAE v4.0 during the 3 months of treatment with imatinib and pioglitazone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with MMR, MR4.0, MR4.5</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Proportion of patients with MMR, MR4.0 and MR4.5 at 3, 6 and 12 months after imatinib discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from imatinib discontinuation until loss of MMR</measure>
    <time_frame>Through study completion (five years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of loss of complete cytogenetic response</measure>
    <time_frame>Through study completion (five years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach MMR after restarting imatinib</measure>
    <time_frame>Through study completion (five years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival after imatinib discontinuation</measure>
    <time_frame>Through study completion (five years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival after imatinib discontinuation</measure>
    <time_frame>Through study completion (five years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival after imatinib discontinuation</measure>
    <time_frame>Through study completion (five years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leukemia, Chronic Myeloid</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone will be given 30 mg/day, orally, for 3 months, before imatinib discontinuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>30 mg/day, orally, for 3 months, before imatinib discontinuation</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>imatinib discontinuation</intervention_name>
    <description>imatinib discontinuation after 3 months of pioglitazone</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CML in chronic phase

          -  treatment with imatinib for 3 or more years

          -  MR4.5 (RQ-PCR&lt; ou =0.0032%) confirmed by 4 RQ-PCR tests for BCR-ABL in the last 2
             years (2 tests within the last 6 months)

          -  Eastern Cooperative Oncology Group Performance Status (ECOG) 0-2

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 reference
             level

          -  Bilirubins ≤ 1.5 reference level

          -  Contraceptive precautions for women

        Exclusion Criteria:

          -  Patients less than 18 years

          -  Severe organ disfunction (liver or kidney)

          -  Severe cardiovascular disease: grade I-IV from New York Heart Association (NYHA) or
             acute myocardial infarction in the last six months, symptomatic arrhythmias

          -  Fluid retention grade 3 or 4

          -  Osteoporosis in treatment

          -  Patients with previous CML in accelerated or blast phase or blast or Philadelphia
             positive (Ph+) acute lymphoid leukemia (ALL)

          -  BCR-ABL mutations related to resistance

          -  Previous allogeneic bone marrow transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katia B Pagnano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katia B Pagnano, MD</last_name>
    <phone>55-19-35218740</phone>
    <email>kborgia@unicamp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Márcia T Delamain, MD</last_name>
    <phone>55-19-35218740</phone>
    <email>marciatd@unicamp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Hematologia e Hemoterapia - Universidade Estadual de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-868</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katia B Pagnano, MD</last_name>
      <phone>55-19-35218740</phone>
      <email>kborgia@unicamp.br</email>
    </contact>
    <contact_backup>
      <last_name>Márcia T Delamain, MD</last_name>
      <phone>55-19-35218740</phone>
      <email>marciatd@unicamp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Katia B Pagnano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Márcia T Delamain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gislaine O Duarte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erich V De Paula, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmino A De Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Piazza R, Valsecchi MG, Kim DW. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011 Apr 6;103(7):553-61. doi: 10.1093/jnci/djr060. Epub 2011 Mar 21. Erratum in: J Natl Cancer Inst. 2016 Sep;108(9). pii: djw211. doi: 10.1093/jnci/djw211. Piazza, Rocco [added].</citation>
    <PMID>21422402</PMID>
  </reference>
  <reference>
    <citation>Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013 May 30;121(22):4439-42. doi: 10.1182/blood-2013-03-490003. Epub 2013 Apr 25.</citation>
    <PMID>23620577</PMID>
  </reference>
  <reference>
    <citation>Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.</citation>
    <PMID>20965785</PMID>
  </reference>
  <reference>
    <citation>Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, Mahon FX. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007 Jan 1;109(1):58-60. Epub 2006 Sep 14.</citation>
    <PMID>16973963</PMID>
  </reference>
  <reference>
    <citation>Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010 Oct;24(10):1719-24. doi: 10.1038/leu.2010.185. Epub 2010 Sep 2.</citation>
    <PMID>20811403</PMID>
  </reference>
  <reference>
    <citation>Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013 Jul 25;122(4):515-22. doi: 10.1182/blood-2013-02-483750. Epub 2013 May 23.</citation>
    <PMID>23704092</PMID>
  </reference>
  <reference>
    <citation>Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012 Jun;97(6):903-6. doi: 10.3324/haematol.2011.056853. Epub 2011 Dec 16.</citation>
    <PMID>22180435</PMID>
  </reference>
  <reference>
    <citation>Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012 Oct;26(10):2172-5. doi: 10.1038/leu.2012.104. Epub 2012 Apr 16. Review.</citation>
    <PMID>22504141</PMID>
  </reference>
  <reference>
    <citation>Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.</citation>
    <PMID>24323036</PMID>
  </reference>
  <reference>
    <citation>Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S, Kim JA, Kim HS, Cho EH, Kwak JY. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res. 2012 Jun;36(6):689-93. doi: 10.1016/j.leukres.2012.02.011. Epub 2012 Mar 5.</citation>
    <PMID>22398220</PMID>
  </reference>
  <reference>
    <citation>Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013 May 9;121(19):3818-24. doi: 10.1182/blood-2012-10-462291. Epub 2013 Mar 20.</citation>
    <PMID>23515925</PMID>
  </reference>
  <reference>
    <citation>Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec;88(12):1024-9. doi: 10.1002/ajh.23560. Epub 2013 Sep 12.</citation>
    <PMID>23913852</PMID>
  </reference>
  <reference>
    <citation>Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX. Curing chronic myeloid leukemia. Curr Hematol Malig Rep. 2012 Jun;7(2):103-8. doi: 10.1007/s11899-012-0117-2. Review.</citation>
    <PMID>22410764</PMID>
  </reference>
  <reference>
    <citation>Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, Beressi JP, Verhoeyen E, Raggueneau V, Maneglier B, Castaigne S, Chomienne C, Chrétien S, Rousselot P, Leboulch P. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature. 2015 Sep 17;525(7569):380-3. doi: 10.1038/nature15248. Epub 2015 Sep 2.</citation>
    <PMID>26331539</PMID>
  </reference>
  <reference>
    <citation>Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol. 2006 Apr;58(1):1-14. Epub 2006 Jan 18. Review.</citation>
    <PMID>16388966</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>September 10, 2017</last_update_submitted>
  <last_update_submitted_qc>September 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Katia B. B. Pagnano</investigator_full_name>
    <investigator_title>Hematologist, Hemocentro-Unicamp</investigator_title>
  </responsible_party>
  <keyword>BCR-ABL Positive</keyword>
  <keyword>Leukemia, Chronic Myeloid</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

